Neurocrine Biosciences Inc (NBIX)vsViatris Inc (VTRS)
NBIX
Neurocrine Biosciences Inc
$127.68
-1.56%
HEALTHCARE · Cap: $13.12B
VTRS
Viatris Inc
$13.20
-2.22%
HEALTHCARE · Cap: $15.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 400% more annual revenue ($14.30B vs $2.86B). NBIX leads profitability with a 16.7% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.07. NBIX earns a higher WallStSmart Score of 75/100 (B+).
NBIX
Strong Buy75
out of 100
Grade: B+
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+37.1%
Fair Value
$218.56
Current Price
$127.68
$90.88 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Strong operational efficiency at 28.2%
Revenue surging 28.3% year-over-year
Earnings expanding 47.7% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Weak financial health signals
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : NBIX
The strongest argument for NBIX centers on PEG Ratio, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.7% and operating margin at 28.2%. Revenue growth of 28.3% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bear Case : NBIX
The primary concerns for NBIX are P/E Ratio, Piotroski F-Score.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
NBIX profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
NBIX is growing revenue faster at 28.3% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
NBIX scores higher overall (75/100 vs 50/100), backed by strong 16.7% margins and 28.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neurocrine Biosciences Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric diseases and disorders in the United States. The company is headquartered in San Diego, California.
Visit Website →Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?